Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net sales	$ 571,644	$ 553,979
Cost of goods sold	254,276	242,217
Gross profit	317,368	311,762
Selling, general and administrative expense	193,692	207,581
Research and Development Expense	49,303	47,575
Segment profit (loss)	74,373	56,606
Interest expense	5,690	5,986
Foreign exchange (gains) losses, net	928	1,280
Marketable Securities, Unrealized (Gain) Loss	(827,671)	(1,059,230)
Other Nonoperating Income (Expense)	3,273	18,696
Income before income taxes	898,699	1,127,266
(Provision) benefit for income taxes	(212,787)	(262,071)
Net income attributable to Bio-Rad	$ 685,912	$ 865,195
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 22.97	$ 29.03
Weighted average common shares - basic	29,865	29,801
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 22.72	$ 28.74
Weighted average common shares - diluted	30,196	30,104